3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Plasmacytoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Margins of Excision
1
Homologous Recombination Deficient Solid Tumors
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Acrocephalosyndactylia
1
Interventions
pembrolizumab
156
Gemcitabine
139
Capecitabine
121
Paclitaxel
119
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
93
Cisplatin
90
Irinotecan
88
Carboplatin
85
Radiosurgery
83
Cyclophosphamide
71
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
Drug Combinations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled